Bipolar Androgen Therapy Effective After Enzalutamide in mCRPC
One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.
Source: OncLive